Atlas Trials

Incidence and Prognostic Significance of HER-2 Status Discordance Between Primary Breast Cancer and Paired Recurrent/Metastatic Lesions

Clinical trial NCT05510037 · COMPLETED

Trial details

NCT number
NCT05510037
Sponsor
Fudan University
Status
COMPLETED
Study type
OBSERVATIONAL
Breast Cancer
Start date
2021-01-01
Primary completion
2022-06-01
Enrollment
1299

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.